产品
编 号：F745010
分子式：C21H17N3O3
分子量：359.38
分子式：C21H17N3O3
分子量：359.38
产品类型
规格
价格
是否有货
结构图
CAS No: 1425944-33-7
产品详情
生物活性：
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis.
体内研究：
CYD-4-61 (2.5 mg/kg; i.p.; once daily for 7 d) inhibits triple-negative breast tumor growth in xenograft model in mice.Animal Model:Triple-negative breast cancer MDA-MB-231 xenograft model in mice
Dosage:2.5 mg/kg
Administration:Intraperitoneal injection; once daily for 7 consecutive days
Result:Significantly suppressed the growth of MDA-MB-231 tumors with an inhibition rate of 55%.
体外研究：
CYD-4-61 (compound 49) (0-10 μM; 72 h) exhibits significantly improved antiproliferative activity with IC50s of 0.07 μM against triple-negative breast cancer MDA-MB-231 and 0.06 μM against ER-positive breast cancer MCF-7 cell lines, respectively.CYD-4-61 (1 μM; 72 h) induces apoptosis among MCF-7 and MDA-MB-231 cells.CYD-4-61 (5 μM and 10 μM; ) increases the level of cells with apoptotic bodies in MDA-MB-231 and MCF-7 cells.CYD-4-61 (5 μM; 0-48 h) decreases the level of p-Bax, but increases the levle of total Bax protein, cytochrome c, and several protein markers related to apoptosis.
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis.
体内研究：
CYD-4-61 (2.5 mg/kg; i.p.; once daily for 7 d) inhibits triple-negative breast tumor growth in xenograft model in mice.Animal Model:Triple-negative breast cancer MDA-MB-231 xenograft model in mice
Dosage:2.5 mg/kg
Administration:Intraperitoneal injection; once daily for 7 consecutive days
Result:Significantly suppressed the growth of MDA-MB-231 tumors with an inhibition rate of 55%.
体外研究：
CYD-4-61 (compound 49) (0-10 μM; 72 h) exhibits significantly improved antiproliferative activity with IC50s of 0.07 μM against triple-negative breast cancer MDA-MB-231 and 0.06 μM against ER-positive breast cancer MCF-7 cell lines, respectively.CYD-4-61 (1 μM; 72 h) induces apoptosis among MCF-7 and MDA-MB-231 cells.CYD-4-61 (5 μM and 10 μM; ) increases the level of cells with apoptotic bodies in MDA-MB-231 and MCF-7 cells.CYD-4-61 (5 μM; 0-48 h) decreases the level of p-Bax, but increases the levle of total Bax protein, cytochrome c, and several protein markers related to apoptosis.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备